Antimicrobial Resistance of Escherichia coli for Uncomplicated Cystitis: Korean Antimicrobial Resistance Monitoring System
- PMID: 39596768
- PMCID: PMC11591001
- DOI: 10.3390/antibiotics13111075
Antimicrobial Resistance of Escherichia coli for Uncomplicated Cystitis: Korean Antimicrobial Resistance Monitoring System
Erratum in
-
Correction: Yu et al. Antimicrobial Resistance of Escherichia coli for Uncomplicated Cystitis: Korean Antimicrobial Resistance Monitoring System. Antibiotics 2024, 13, 1075.Antibiotics (Basel). 2025 Feb 25;14(3):234. doi: 10.3390/antibiotics14030234. Antibiotics (Basel). 2025. PMID: 40149138 Free PMC article.
Abstract
Objectives: Uncomplicated cystitis is a leading form of bacterial UTI; the most common causative bacterium worldwide is Escherichia coli. This internet-based, prospective, multicenter, and national observational study aimed to report the antimicrobial resistance of E. coli in patients with uncomplicated cystitis through the use of the Korean Antimicrobial Resistance Monitoring System (KARMS) in 2023. Results: Data for a total of 654 patients were retrieved from the KARMS database. The mean (standard deviation) patient age was 55.9 (18.3) years. The numbers of postmenopausal women and patients with recurrent cystitis were 381 (59.4%) and 78 (11.9%), respectively. Regarding antimicrobial susceptibility, 96.8% were susceptible to fosfomycin, 98.9% to nitrofurantoin, 50.9% to ciprofloxacin, and 82.4% to cefotaxime. Extended-spectrum beta-lactamase positivity was 14.4% (89/616), and was significantly higher in tertiary hospitals (24.6%, p < 0.001) and recurrent cystitis (27.6%, p < 0.001). Fluoroquinolone resistance was significantly higher in tertiary hospitals (57.8%, p < 0.001), postmenopausal women (54.2%, p < 0.001), and recurrent cystitis (70.3%, p < 0.001). In addition, postmenopausal status (95% confidence interval [CI]: 1.44-3.17, odds ratio [OR] 2.13, p < 0.001), recurrent cystitis (95% CI: 1.40-4.66, OR 2.56, p = 0.002) and tertiary hospitals (95% CI: 1.00-2.93, OR 1.71, p = 0.049) were associated with significantly increased fluoroquinolone resistance. Methods: Any female patient diagnosed with clinical uncomplicated cystitis and microbiologically proven E. coli infection in 2023 was eligible for this study. Patient data were obtained from the web-based KARMS database. The antimicrobial susceptibility of E. coli was analyzed according to clinical factors, including hospital region, hospital type, menopause status, and recurrence status. Conclusions: The antimicrobial resistance of E. coli in patients with uncomplicated cystitis in the Republic of Korea has reached a serious level, especially in fluoroquinolone resistance. Therefore, major efforts should be made to reduce antimicrobial resistance.
Keywords: Escherichia coli; antibiotic resistance; cystitis; urinary tract infection.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures


Similar articles
-
Nationwide surveillance of antimicrobial resistance for uncomplicated cystitis in 2023: Conducted by the Korean Association of Urogenital Tract Infection and Inflammation.Investig Clin Urol. 2025 Mar;66(2):161-171. doi: 10.4111/icu.20240302. Investig Clin Urol. 2025. PMID: 40047130 Free PMC article.
-
Emergence of Extended spectrum β-lactamase (ESBL) and carbapenemase producing Escherichia coli (E. coli) in mid-stream urine cultures of patients presenting in outpatient department of tertiary care hospital with uncomplicated cystitis (2016-2022): A retrospective analysis of Laboratory data.Pak J Med Sci. 2025 Jan;41(1):275-280. doi: 10.12669/pjms.41.1.3379. Pak J Med Sci. 2025. PMID: 39867801 Free PMC article.
-
Isolation of fluoroquinolone-resistant rectal Escherichia coli after treatment of acute uncomplicated cystitis.J Antimicrob Chemother. 2005 Jul;56(1):243-6. doi: 10.1093/jac/dki169. Epub 2005 May 23. J Antimicrob Chemother. 2005. PMID: 15911548 Clinical Trial.
-
The current management strategies for community-acquired urinary tract infection.Infect Dis Clin North Am. 2003 Jun;17(2):303-32. doi: 10.1016/s0891-5520(03)00004-7. Infect Dis Clin North Am. 2003. PMID: 12848472 Review.
-
Antibiotic Resistance Among Uropathogenic Escherichia coli.Pol J Microbiol. 2019 Dec;68(4):403-415. doi: 10.33073/pjm-2019-048. Epub 2019 Dec 5. Pol J Microbiol. 2019. PMID: 31880885 Free PMC article. Review.
Cited by
-
Correction: Yu et al. Antimicrobial Resistance of Escherichia coli for Uncomplicated Cystitis: Korean Antimicrobial Resistance Monitoring System. Antibiotics 2024, 13, 1075.Antibiotics (Basel). 2025 Feb 25;14(3):234. doi: 10.3390/antibiotics14030234. Antibiotics (Basel). 2025. PMID: 40149138 Free PMC article.
References
-
- Bonkat G., Bruyère R.B.F., Cai T., Geerlings S.E., Köves B., Kranz J., Schubert S., Pilatz A., Veeratterapillay R., Wagenlehner F. EAU Guidelines on Urological Infections. Eur. Assoc. Urol. 2024;18:22–26. - PubMed
LinkOut - more resources
Full Text Sources